Audit and Inspections

• Inspection of B-Well Study, carried out by the State Office for Health and Social Affairs, Berlin, 22. April to 23. April 2026
• Inspection of study BI 1220.7, carried out by the US Food and Drug Administration (FDA), 31. March to 3. April 2014.
• Study audit for Bionor Vacc-4x IMiD/-2010/1, initiated by CRO Aptiv Solutions, 7 and 8 November 2013.
• Study audit on A4001095, initiated by the sponsor Pfizer,14. and 15. May 2013.
• Study audit on GS-US-264-0106, initiated by the sponsor Gilead Sciences,21. and 22. November 2011.
• Study audit on ING114467, initiated by sponsor GlaxoSmithKline, 12. and 13. October 2011.
• Study audit on BI 1100.1486, initiated by sponsor Boehringer Ingelheim, 1. April 2009.
• Inspection of the study BI 1182.107, carried out by the State Office for Health and Social Affairs, BerlinJune/July 2008.
• Study audit on AI 424-138 (CASTLE), initiated by sponsor Bristol-Myers-Squibb, November 2006.
• GCP audit of the WV16789 study, initiated by the sponsor ROCHE, Mai 2004.
• Study audit on BI 1182.52, initiated by sponsor Boehringer Ingelheim, January 2003.
• GCP audit of the APV 30005 study, initiated by the sponsor GlaxoSmithKline, October 2002.